vaccine manufacturers

Delhi, April 20: Prime Minister Narendra Modi on Tuesday interacted with vaccine manufacturers from across the country via video conferencing and urged them to continuously scale up the production capacity so that everyone in India can be vaccinated as soon as possible.

Commending the scientists for their efforts, PM Modi credited them for developing and manufacturing vaccines in record time. Noting the fact that vaccines manufactured in India are the cheapest, PM Modi said that India the world’s largest vaccine program is underway in India.

PM Modi said that the biggest strength of our vaccine industry is its ‘Samarthya, Sansadhan, and Seva Bhaav’, and these are what make them a vaccine leader in the world.

PM Modi remarked that throughout this process of developing and manufacturing vaccines, “the country has constantly worked with the spirit of public-private partnership under the ‘Mission Covid Suraksha’, and created an end-to-end vaccine development ecosystem”.

“The government ensured that all the vaccine manufacturers not only get all possible help and logistic support, but also the process of vaccine approval is speedy and scientific,” the prime minister said. He also assured all possible support and a smooth approval process for the vaccine candidates which are currently under trial phase.


Also Read: COVID-19 vaccine for all above age of 18 years from May 1: Government

The prime minister said the health infrastructure of India’s private sector has played a big role in the country’s fight against Covid-19 and in the coming days, the private sector will play an even more active role in the vaccination drive. “This will require better coordination between hospitals and industry,” he said.

During the virtual conference, the vaccine manufacturers thanked the prime minister for the government’s decision to allow vaccination for everyone above the age of 18, and various steps are taken to give more incentives and flexibility.

They also discussed their plans to ramp up production, upcoming vaccine candidates, and research on the new variants.